COVID-19 Archives - Page 5 of 20 - Dr Amin Azhari

A quick, high-yield synthesis of molnupiravir, an investigational COVID antiviral pill

As SARS-CoV-2 continues to spread and mutate, it’s important to identify new treatment options. Molnupiravir is an investigational oral antiviral being developed for the treatment of COVID-19, and has been submitted for review by the U.S. Food and Drug Administration. Researchers now report in ACS Central Science that they have engineered enzymes to help manufacture the pill, resulting in a much shorter and higher-yielding synthesis than current methods.

Originally developed to treat influenza, molnupiravir works by causing viruses to make errors when copying their own RNA, introducing mutations that inhibit replication. Recently, interim phase 3 clinical trial findings indicated that molnupiravir reduced the risk of hospitalization and death from COVID-19 for newly diagnosed, at-risk patients, and that it worked equally well against different SARS-CoV-2 variants. John McIntosh, Patrick Fier and colleagues at Merck and Codexis set out to develop a shorter, higher-yielding and sustainable way to synthesize the molecule.

The researchers developed a three-step synthesis of molnupiravir from a sugar molecule called ribose. They identified enzymes or chemical treatments to sequentially add the appropriate chemical groups to ribose to generate the molecule. For the second step of the synthesis, the team identified bacterial enzymes that weakly catalyzed the desired reactions. Using in vitro evolution, they greatly enhanced these enzymes’ activities. The new synthetic route, which also included a phosphate recycling strategy, was 70% shorter and had a seven-fold higher overall yield than the original route.

Release date: 03 November 2021
Source: American Chemical Society

Statins linked to reduced risk of death from COVID-19 in major population study

Statins are a recommended and common intervention for preventing cardiovascular events by reducing levels of lipoprotein cholesterol in the blood. During the pandemic, it has been debated whether statins influence the risk of death from COVID-19. Researchers at Karolinska Institutet have now conducted the largest population study to date in the field. The study, which is published in PLOS Medicine, indicates that statin treatment slightly lowers COVID-19 mortality.

Statins are used to lower the cholesterol level – the lipid count – in the blood and are a common preventative treatment in patients at high risk of cardiovascular events.

During the pandemic, the question of whether statins can reduce COVID-19 mortality via their effects on coagulation and the immune system has engaged scientists and doctors.

Earlier studies have not provided an unequivocal answer and have often suffered from the limitation that they have only included hospital inpatients. Researchers at Karolinska Institutet have now carried out the largest population study to date on the relationship between statins and COVID-19 mortality.

Release date: 14 October 2021
Source: Karolinska Institutet

Covid-19

How many people get ‘long COVID?’ More than half

More than half of the 236 million people who have been diagnosed with COVID-19 worldwide since December 2019 will experience post-COVID symptoms — more commonly known as “long COVID” — up to six months after recovering, according to Penn State College of Medicine researchers. The research team said that governments, health care organizations and public health professionals should prepare for the large number of COVID-19 survivors who will need care for a variety of psychological and physical symptoms.

During their illnesses, many patients with COVID-19 experience symptoms, such as tiredness, difficulty breathing, chest pain, sore joints and loss of taste or smell.

Until recently, few studies have evaluated patients’ health after recovering from the coronavirus. To better understand the short- and long-term health effects of the virus, the researchers examined worldwide studies involving unvaccinated patients who recovered from COVID-19. According to the findings, adults, as well as children, can experience several adverse health issues for six months or longer after recovering from COVID-19.

The researchers conducted a systematic review of 57 reports that included data from 250,351 unvaccinated adults and children who were diagnosed with COVID-19 from December 2019 through March 2021. Among those studied, 79% were hospitalized, and most patients (79%) lived in high-income countries. Patients’ median age was 54, and the majority of individuals (56%) were male.

The researchers analyzed patients’ health post-COVID during three intervals at one month (short-term), two to five months (intermediate-term) and six or more months (long-term).

According to the findings, survivors experienced an array of residual health issues associated with COVID-19. Generally, these complications affected a patient’s general well-being, their mobility or organ systems. Overall, one in two survivors experienced long-term COVID manifestations. The rates remained largely constant from one month through six or more months after their initial illness.

The investigators noted several trends among survivors, such as:

General well-being: More than half of all patients reported weight loss, fatigue, fever or pain.
Mobility: Roughly one in five survivors experienced a decrease in mobility.
Neurologic concerns: Nearly one in four survivors experienced difficulty concentrating.
Mental health disorders: Nearly one in three patients were diagnosed with generalized anxiety disorders.
Lung abnormalities: Six in ten survivors had chest imaging abnormality and more than a quarter of patients had difficulty breathing.
Cardiovascular issues: Chest pain and palpitations were among the commonly reported conditions.
Skin conditions: Nearly one in five patients experienced hair loss or rashes.
Digestive issues: Stomach pain, lack of appetite, diarrhea and vomiting were among the commonly reported conditions.

Release date: 13 October 2021
Source: Penn State

COVID-19-Related Parenting Stress Impacted Eating Habits of Children

The incredible stress parents experienced during the COVID-19 pandemic had a negative effect on the eating habits of their children, according to a new study by researchers at the University of Houston College of Education.

When stay-at-home mandates were ordered and school went virtual at the onset of the pandemic, many parents suddenly had to juggle multiple roles such as caregiver, employee and educator. Leslie Frankel, associate professor of human development and family studies, said all those responsibilities took a toll on parents’ mental health, and in turn, what and how much their children were consuming.

Previous research has shown that stress in general is known to have a negative impact on parent-child feeding interactions, but new findings published in the journal Current Psychology reveal COVID-19 only magnified the problem.

Release date: 12 October 2021
Source: University of Houston

Covid-19, Covid-19, Covid-19, Covid-19, Covid-19, Covid-19, Covid-19, Covid-19, Covid-19, Neurologic disorders

Alzheimer’s and Covid-19 share a genetic risk factor

An anti-viral gene that impacts the risk of both Alzheimer’s disease and severe Covid-19 has been identified by a UCL-led research team.

The researchers estimate that one genetic variant of the OAS1 gene increases the risk of Alzheimer’s disease by about 3-6% in the population as a whole, while related variants on the same gene increase the likelihood of severe Covid-19 outcomes.

The findings, published in Brain, could open the door for new targets for drug development or tracking disease progression in either disease, and suggest that treatments developed could be used for both conditions. The findings also have potential benefits for other related infectious conditions and dementias.

Release date: 08 October 2021
Source: University College London

COVID-19: Coughing without masks, distancing alone is not enough

To prevent the spread of COVID-19 indoors, the two metres physical distancing guideline is not enough without masks, according to researchers from Quebec, Illinois, and Texas. However, wearing a mask indoors can reduce the contamination range of airborne particles by about 67 percent.

“Mask mandates and good ventilation are critically important to curb the spread of more contagious strains of COVID-19, especially during the flu season and winter months as more people socialize indoors,” says Saad Akhtar, a former doctoral student under the supervision of Professor Agus Sasmito at McGill University.

While most public health guidelines recommend physical distancing of two metres for people from different households, the researchers say distancing alone is not enough to prevent the spread of COVID-19. In a study published in Building and Environment, the researchers found that when people are unmasked, more than 70 percent of airborne particles pass the two metres threshold within the 30 seconds. By contrast, less than 1 percent of particles cross the two-metre mark if masks are worn.

Release date: 05 October 2021
Source: McGill University

Those under 40 more likely than older adults to recover COVID-related smell and taste loss

Ongoing survey tracking smell and taste recovery of COVID-19 survivors shows 4 out of every 5 recover senses within 6 months.

RICHMOND, Va. (October 5, 2021) — Sense of smell or taste returns within six months for 4 out of every 5 COVID-19 survivors who have lost these senses, and those under 40 are more likely to recover these senses than older adults, an ongoing Virginia Commonwealth University study found.

Among 798 respondents to the ongoing COVID-19 smell and taste loss survey who had tested positive for COVID-19 and reported a loss of smell or taste, participants who were younger than 40 recovered their sense of smell at a higher rate than those older than 40, according to study results published in the American Journal of Otolaryngology last month. The VCU study requires survey participants to be 18 years or older.

What symptoms COVID-19 survivors experienced and what pre-existing conditions they had also offered insights into their recovery. Those with a history of head injury were less likely to recover their sense of smell. Recovery was also less likely for those who had shortness of breath during COVID-19. However, those with nasal congestion had a higher likelihood of smell recovery.

Release date: 05 October 2021
Source: Virginia Commonwealth University

COVID-19 has caused the biggest decrease in life expectancy since World War II

The research team assembled an unprecedented dataset on mortality from 29 countries, spanning most of Europe, the US and Chile – countries for which official death registrations for 2020 had been published. They found that 27 of the 29 countries saw reductions in life expectancy in 2020, and at a scale which wiped out years of progress on mortality, according to the paper published today in the International Journal of Epidemiology.

Women in 15 countries and men in 10 countries were found to have a lower expectancy at birth in 2020 than in 2015, a year in which life expectancy was already negatively affected by a significant flu season.

According to the study’s co-lead author Dr José Manuel Aburto, ‘For Western European countries such as Spain, England and Wales, Italy, Belgium, among others, the last time such large magnitudes of declines in life expectancy at birth were observed in a single year was during WW-II.

But, he says, the scale of the life expectancy losses was stark across most countries studied, ‘Twenty two countries included in our study experienced larger losses than half a year in 2020. Females in eight countries and males in 11 countries experienced losses larger than a year. To contextualize, it took on average 5.6 years for these countries to achieve a one-year increase in life expectancy recently: progress wiped out over the course of 2020 by COVID-19.’

Release date: 27 September 2021
Source: University of Oxford

Public Health, Public Health, Public Health, Public Health, Public Health, Public Health, Public Health, Public Health, Public Health

Poorly Circulated Room Air Raises Potential Exposure to Contaminants by up to 6 Times

Berkeley Lab experiments quantify the effects of overhead heating on room air mixing with implications for COVID-safe meetings and classrooms. Having good room ventilation to dilute and disperse indoor air pollutants has long been recognized, and with the COVID-19 pandemic its importance has become all the more heightened. But new experiments by indoor air researchers at Lawrence Berkeley National Laboratory (Berkeley Lab) show that certain circumstances will result in poor mixing of room air, meaning airborne contaminants may not be effectively dispersed and removed by building level ventilation.

Using CO2 as a tracer to track small respiratory aerosols that travel with air currents in a room, the Berkeley Lab team found that when overhead vents (or diffusers) are supplying heated air, it created thermally stratified conditions that block the flow of clean air down to the “breathing zone” in the middle height of the room. As a result, even when people are sitting more than 6 feet from each other, some occupants may be exposed to respiratory aerosols from others at a rate 5 to 6 times higher than if the same room were well mixed.

Their study, “Measured influence of overhead HVAC on exposure to airborne contaminants from simulated speaking in a meeting and a classroom,” was published recently in the journal Indoor Air.

Release date: 22 September 2021
Source: DOE/Lawrence Berkeley National Laboratory

Public Health

COVID-19 Nasal Vaccine Candidate Effective At Preventing Disease Transmission

IN THROUGH THE NOSE…

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in developing intramuscular vaccines against SARS-CoV- 2, such as the readily available Pfizer, Moderna and Johnson & Johnson vaccines, nothing yet – like a nasal vaccine – has been approved to provide mucosal immunity in the nose, the first barrier against the virus before it travels down to the lungs. But now, we’re one step closer.

Navin Varadarajan, M.D. Anderson Professor of Chemical and Biomolecular Engineering at the Cullen College of Engineering, and his colleagues are reporting in iScience the development of an intranasal subunit vaccine that provides durable local immunity against inhaled pathogens.

Release date: 15 September 2021
Source: University of Houston

Tag Archive for: COVID-19